Key Takeaways
- GO Virginia has approved $14.3 million for Project VITAL to enhance biotechnology innovation in Virginia.
- The initiative aims to create 1,315 jobs and generate an economic impact of $40.8 million over five years.
- Virginia Tech will collaborate with local partners to strengthen the biotechnology workforce and support startups in the region.
Project VITAL to Boost Virginia’s Biotechnology Sector
Virginia Tech is set to play a pivotal role in Project VITAL, a significant initiative to accelerate biotechnology innovation across Virginia. The initiative has received a $14.3 million funding approval from GO Virginia, which aims to strengthen partnerships and establish new research cores while expanding workforce development programs. This funding is part of Governor Glenn Youngkin’s broader $90 million investment in advancing biotechnology, which includes $27 million allocated to the Fralin Biomedical Research Institute at Virginia Tech to expand clinical research capabilities.
The Roanoke Blacksburg Innovation Alliance (RBIA) will partner with Virginia Tech and Carilion Clinic to lead the project in Region 2. With a focused investment of $4.9 million, Project VITAL aims to enhance the region’s prowess in medical devices, oncology research, and neurotechnology. Crucial enhancements are expected in Southwest Virginia’s innovation corridor through programs that support biomedical startups and provide resources for emerging companies.
Brandy Salmon, associate vice president for innovation and partnerships at Virginia Tech, highlighted the importance of moving innovations from the lab to market for economic impact. Collaborating institutions like Virginia Western Community College and the Roanoke Blacksburg Technology Council will work to boost the region’s biotechnology talent pool. The initiative encompasses cities and counties throughout the GO Virginia Region 2 area.
Other regions will similarly contribute to biotechnology advancement, with Virginia Commonwealth University leading efforts in Region 4 and the University of Virginia collaborating in Region 9. Overall, Project VITAL is anticipated to create 1,315 jobs and foster a total economic impact of $40.8 million in the coming five years.
William E. Amos, chairman of GO Virginia Region 2, emphasized the collaborative nature of this initiative, showcasing the potential of public-private partnerships to create job opportunities and drive innovation. Erin Burcham, president of RBIA, noted that this funding marks a crucial moment for the region’s biotechnology ecosystem, providing advanced facilities, talent recruitment, and support for new startups.
Aileen Helsel from Carilion Clinic expressed enthusiasm for partnering on this initiative, focusing on resources that assist medical device startups through federal regulations. Michael Friedlander of Virginia Tech underscored the project’s role in advancing biomedical innovation and the regional cooperation that has emerged over the last decade in life and health sciences.
John Provo, executive director of Virginia Tech’s Center for Economic and Community Engagement, stated that Project VITAL exemplifies the mission to connect academic research with community needs, creating pathways for innovation that lead to high-wage jobs and address significant health care challenges.
The content above is a summary. For more details, see the source article.